Healthcare provider profile · identity verified

Anna Brand, APRN

Nurse Practitioner · NEWMARKET, NH · NPI 1912438102

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	375	111
Losartan Potassium	Losartan Potassium	238	65
Lisinopril	Lisinopril	236	82
Levothyroxine Sodium	Levothyroxine Sodium	224	71
Amlodipine Besylate	Amlodipine Besylate	215	66
Omeprazole	Omeprazole	193	60
Rosuvastatin Calcium	Rosuvastatin Calcium	123	43
Gabapentin	Gabapentin	122	40
Albuterol Sulfate Hfa	Albuterol Sulfate	106	35
Hydrochlorothiazide	Hydrochlorothiazide	97	39
Famotidine	Famotidine	96	22
Furosemide	Furosemide	93	29
Sertraline Hcl	Sertraline Hcl	92	35
Metoprolol Succinate	Metoprolol Succinate	85	31
Pregabalin	Pregabalin	83	12
Duloxetine Hcl	Duloxetine Hcl	82	22
Metoprolol Tartrate	Metoprolol Tartrate	78	25
Fluoxetine Hcl	Fluoxetine Hcl	76	18
Metformin Hcl	Metformin Hcl	74	27
Trazodone Hcl	Trazodone Hcl	74	25
Oxycodone Hcl	Oxycodone Hcl	73	suppressed
Lorazepam	Lorazepam	71	26
Atenolol	Atenolol	64	21
Fluticasone Propionate	Fluticasone Propionate	55	30
Mounjaro	Tirzepatide	55	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	55	17
Trulicity	Dulaglutide	54	suppressed
Metformin Hcl Er	Metformin Hcl	51	22
Allopurinol	Allopurinol	50	15
Glipizide	Glipizide	50	19
Ozempic	Semaglutide	50	12
Diclofenac Sodium	Diclofenac Sodium	49	11
Eliquis	Apixaban	49	14
Bupropion Xl	Bupropion Hcl	48	18
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	45	17
Pantoprazole Sodium	Pantoprazole Sodium	45	16
Paroxetine Hcl	Paroxetine Hcl	44	11
Alendronate Sodium	Alendronate Sodium	42	suppressed
Jardiance	Empagliflozin	40	16
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	39	suppressed
Breo Ellipta	Fluticasone/Vilanterol	36	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	35	suppressed
Simvastatin	Simvastatin	33	16
Hydroxyzine Hcl	Hydroxyzine Hcl	30	suppressed
Diazepam	Diazepam	29	suppressed
Montelukast Sodium	Montelukast Sodium	29	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	29	suppressed
Ezetimibe	Ezetimibe	28	11
Pravastatin Sodium	Pravastatin Sodium	27	12
Spironolactone	Spironolactone	27	suppressed
Alprazolam	Alprazolam	26	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	26	suppressed
Potassium Chloride	Potassium Chloride	26	suppressed
Prednisone	Prednisone	26	25
Zolpidem Tartrate	Zolpidem Tartrate	26	suppressed
Aripiprazole	Aripiprazole	24	suppressed
Bumetanide	Bumetanide	24	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Nystatin	Nystatin	23	13
Wixela Inhub	Fluticasone Propion/Salmeterol	23	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	22	20
Meloxicam	Meloxicam	22	suppressed
Mirtazapine	Mirtazapine	22	suppressed
Celecoxib	Celecoxib	20	suppressed
Citalopram Hbr	Citalopram Hydrobromide	20	suppressed
Bupropion Hcl Sr	Bupropion Hcl	18	suppressed
Farxiga	Dapagliflozin Propanediol	18	suppressed
Glipizide Er	Glipizide	18	suppressed
Carvedilol	Carvedilol	17	suppressed
Tramadol Hcl	Tramadol Hcl	17	suppressed
Valacyclovir	Valacyclovir Hcl	17	suppressed
Xarelto	Rivaroxaban	16	suppressed
Januvia	Sitagliptin Phosphate	15	suppressed
Symbicort	Budesonide/Formoterol Fumarate	15	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	13
Methylphenidate Er	Methylphenidate Hcl	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	12
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Finasteride	Finasteride	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Dulera	Mometasone/Formoterol	11	suppressed
Epinephrine	Epinephrine	11	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error